Oncopeptides AB (ONPPF)
0.265
-0.13
(-32.72%)
USD |
OTCM |
May 03, 16:00
Oncopeptides Free Cash Flow (Quarterly): -4.947M for Sept. 30, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -4.947M |
| June 30, 2023 | -7.290M |
| March 31, 2023 | -8.539M |
| December 31, 2022 | -9.223M |
| September 30, 2022 | -4.897M |
| June 30, 2022 | -9.982M |
| March 31, 2022 | -17.82M |
| December 31, 2021 | -53.28M |
| September 30, 2021 | -36.63M |
| June 30, 2021 | -41.07M |
| March 31, 2021 | -46.18M |
| December 31, 2020 | -35.51M |
| September 30, 2020 | -44.20M |
| June 30, 2020 | -29.38M |
| Date | Value |
|---|---|
| March 31, 2020 | -32.53M |
| December 31, 2019 | -23.70M |
| September 30, 2019 | -21.27M |
| June 30, 2019 | -12.56M |
| March 31, 2019 | -15.59M |
| December 31, 2018 | -13.31M |
| September 30, 2018 | -10.05M |
| June 30, 2018 | -10.08M |
| March 31, 2018 | -5.004M |
| December 31, 2017 | -4.072M |
| September 30, 2017 | -11.92M |
| June 30, 2017 | -8.283M |
| March 31, 2017 | -7.579M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-53.28M
Minimum
Dec 2021
-4.897M
Maximum
Sep 2022
-24.39M
Average
-22.48M
Median
Free Cash Flow (Quarterly) Benchmarks
| Abliva AB | -0.0813M |
| Karolinska Development AB | -0.6572M |
| Calliditas Therapeutics AB | -- |
| Olink Holding AB | -11.09M |
| BioInvent International AB | -6.574M |